- Home
- CTNT vs VIVS Comparison
CTNT vs VIVS Comparison
Compare CTNT & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNT | VIVS |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTNT | VIVS |
|---|---|---|
| Price | $1.48 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.4K | ★ 67.5K |
| Earning Date | 05-04-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $455,805.00 | N/A |
| Revenue This Year | $235.67 | $42.38 |
| Revenue Next Year | $20.00 | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $1.42 |
| 52 Week High | $2.12 | $5.30 |
Technical Indicators
Market Signals| Indicator | CTNT | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 40.16 |
| Support Level | $1.36 | N/A |
| Resistance Level | $1.50 | $2.11 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 12.33 | 3.92 |
Price Performance
Historical ComparisonAbout CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a one-stop services including Warehousing, Logistics, International trading & Supply Chain Finance, Etc. It operate in single segment Logistics and warehousing services which focuses on providing freight forwarding services for clients shipping goods from the U.S. to mainland China or Hong Kong. Its services include: cargo storage, freight forwarding, U.S. customs clearance, and (iv) labor services and cargo loading and unloading.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.